Coya Therapeutics Shares Fall After Stock Offering Disclosure

Dow Jones

10/24

By Freddy Sebastian

Shares of Coya Therapeutics were lower after disclosing a public offering of its common stock.

Its shares fell 12.8% to $6.09 in premarket trading Friday.

The company said it expects to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered in the proposed offering at the public offering price per share, excluding underwriting discounts and commissions.

The clinical-state biotechnology company plans to use proceeds from the proposed public offering for working capital and other general corporate purposes, including funding its clinical development plan.

Write to Freddy Sebastian at freddy.sebastian@wsj.com

(END) Dow Jones Newswires

October 24, 2025 06:13 ET (10:13 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2577594082"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577594082\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577594082?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 18:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577594082","market":"fut","top_or_hot":-1,"title":"Coya Therapeutics Shares Fall After Stock Offering Disclosure","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Freddy Sebastian \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/COYA\">Coya Therapeutics</a> were lower after disclosing a public offering of its common stock. \n</p>\n<p>\n  Its shares fell 12.8% to $6.09 in premarket trading Friday. \n</p>\n<p>\n  The company said it expects to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered in the proposed offering at the public offering price per share, excluding underwriting discounts and commissions. \n</p>\n<p>\n  The clinical-state biotechnology company plans to use proceeds from the proposed public offering for working capital and other general corporate purposes, including funding its clinical development plan. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Freddy Sebastian at freddy.sebastian@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 24, 2025 06:13 ET (10:13 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coya Therapeutics Shares Fall After Stock Offering Disclosure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoya Therapeutics Shares Fall After Stock Offering Disclosure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-24 18:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Freddy Sebastian \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/COYA\">Coya Therapeutics</a> were lower after disclosing a public offering of its common stock. \n</p>\n<p>\n  Its shares fell 12.8% to $6.09 in premarket trading Friday. \n</p>\n<p>\n  The company said it expects to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered in the proposed offering at the public offering price per share, excluding underwriting discounts and commissions. \n</p>\n<p>\n  The clinical-state biotechnology company plans to use proceeds from the proposed public offering for working capital and other general corporate purposes, including funding its clinical development plan. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Freddy Sebastian at freddy.sebastian@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 24, 2025 06:13 ET (10:13 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2577594082","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577594082","pubTimestamp":1761300780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Coya Therapeutics were lower after disclosing a public offering of its common stock.Its shares fell 12.8% to $6.09 in premarket trading Friday.The company said it expects to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered in the proposed offering at the public offering price per share, excluding underwriting discounts and commissions.The clinical-state biotechnology company plans to use proceeds from the proposed public offering for working capital and other general corporate purposes, including funding its clinical development plan.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","LENZ":"Therapeutics","BK4139":"生物科技","COYA":"COYA THERAPEUTICS INC","BK4007":"制药"},"translate_title":"Coya Therapeutics股价在股票发行披露后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COYA":0.9,"LENZ":1.5},"content_text":"By Freddy Sebastian \n\n\n \n\n\n  Shares of Coya Therapeutics were lower after disclosing a public offering of its common stock. \n\n\n  Its shares fell 12.8% to $6.09 in premarket trading Friday. \n\n\n  The company said it expects to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered in the proposed offering at the public offering price per share, excluding underwriting discounts and commissions. \n\n\n  The clinical-state biotechnology company plans to use proceeds from the proposed public offering for working capital and other general corporate purposes, including funding its clinical development plan. \n\n\n \n\n\n  Write to Freddy Sebastian at freddy.sebastian@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 24, 2025 06:13 ET (10:13 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}